New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction—ICI‐RS 2023
Neurourology and Urodynamics · 2024
DOI: 10.1002/nau.25326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Anthony Kanai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, US. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Disease Progression. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Aims
Benign prostatic enlargement (BPE) can impact lower urinary tract function due to its potential progression to benign prostatic obstruction (BPO). Treatment options include removal of the obstruction by surgery or through use of therapeutics designed to slow growth or reduce tissue stress imposed by muscular stromal components. Inflammation and development of fibrosis can also raise intrinsic tissue stress within the gland, further impacting obstruction. Outflow tract obstruction can also impact emission and ejaculation if the obstruction persists.
Methods
This review summarizes an ICI‐RS think tank considering novel drug treatments that might address BPO caused by progressive development of BPE, as well as manage decompensation changes to bladder function.
Results
Topics included recent advances in our understanding of pathological changes occurring to the prostate and other lower urinary tract tissues during progressive development of BPE, and how prevention or reversal might benefit from the identification of novel drug targets. These included contractile properties of prostatic tissues, the impact of BPE and its effects on bladder function, the deposition of intramural fibrotic tissue with protracted BPO, the role of inflammation in the development of BPE and its progression to BPO. In particular, we discussed current therapeutic options for treating BPE/BPO, and new therapeutic targets, what they treat and their advantage over current medications.
Conclusion
Several new drug targets were identified, including soluble guanylate cyclase (sGC), the receptor for nitric oxide (NO•), and sGC activators that promotes sGC‐mediated cGMP production when sGC is inactivated and unresponsive to NO•.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, US.
- Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, US.
- School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, UK.
- Department of Pharmacology, University of Gothenburg, Gothenburg, SE.
- Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.
- Desai Sethi Institute of Urology, University of Miami Miller School of Medicine, Miami, Florida, US.
Förderung
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Kanai, A., Chakrabarty, B., Winder, M., Hashim, H., Wein, A., Abrams, P., & Fry, C. (2024). New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction—ICI‐RS 2023. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25326
Vancouver
Kanai A, Chakrabarty B, Winder M, Hashim H, Wein A, Abrams P, et al. New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction—ICI‐RS 2023. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25326
BibTeX
@article{Kanai2024,
author = {Kanai, Anthony and Chakrabarty, Basu and Winder, Michael and Hashim, Hashim and Wein, Alan and Abrams, Paul and Fry, Christopher},
title = {New therapeutic targets to prevent benign prostatic enlargement and symptomatic progression to benign prostatic obstruction—ICI‐RS 2023},
journal = {Neurourology and Urodynamics},
year = {2024},
doi = {10.1002/nau.25326}
}
EUVIMED